Lurbinectedin for leiomyosarcoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 21 Sep 2023: Trial started, NCT06088290
  2. 18 Oct 2023: Trial registered, NCT06088290

The trials

NCT06088290: Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

State
Under way
Phase
Phase 3
People
469 taking part
Started
21 Sep 2023
Primary completion
30 Aug 2029
Arms
Doxorubicin (Dose A) + Lurbinectedin (Dose B), Doxorubicin (Dose C) + Lurbinectedin (Dose D)
Results
None posted
  1. 21 Sep 2023: Trial started
  2. 18 Oct 2023: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Lurbinectedin 4 MG Injection [Zepzelca], Zepsyre, Zepzelca.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.